FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040341776> ?p ?o ?g. }

• W2040341776 endingPage "1301" @default.
• W2040341776 startingPage "1281" @default.
• W2040341776 abstract "Drug elimination via glucuronidation pathway is a complex process involving glucuronide excretion. Glucuronide excreted into the gut lumen either directly from the enterocytes or from the hepatobiliary route can be recovered back to the precursor (aglycone) through bacteria-mediated hydrolysis. As a result, the pharmacokinetics [e.g., plasma terminal half-life (T1/2)] of aglycone might be altered. Here, impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone is evaluated using physiologically based pharmacokinetic (PBPK) models with liver and/or intestine as eliminating organs. It is found that compared with its absence, the presence of intestinal glucuronide hydrolysis leads to increases in the oral systemic bioavailability (Fsys) of aglycone. The magnitude of fold increase is positively correlated with the level of metabolism, as metabolic clearance mainly contributes to recycled amount of glucuronide. Although Fsys is independent of the glucuronide efflux in a traditional model and a segregated-flow model of the intestine, dependence of Fsys on the glucuronide efflux can be observed in a segmental segregated-flow model of the intestine and whole-body PBPK models. Interestingly, when the ratio of apical versus basolateral efflux intrinsic clearances (of glucuronide) is fixed, their effects on the intestinal bioavailability and Fsys cease to exist. In addition, glucuronide hydrolysis can lead to a significantly delayed elimination of the aglycone as evidenced by a prolonged (e.g., a 2.1-fold increase) T1/2. Surprisingly, when a pharmacokinetic profile for aglycone is simulated with a flat terminal portion (a reflection of the experimental observations), changes in the aglycone bioavailabilities are limited (i.e., ≤1.3-fold). In conclusion, this study explores the possible role of intestinal glucuronide hydrolysis in the disposition of aglycone via simulations utilizing various PBPK models. The mechanistic observations should be helpful to better understand the complex glucuronidation in vivo. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association Drug elimination via glucuronidation pathway is a complex process involving glucuronide excretion. Glucuronide excreted into the gut lumen either directly from the enterocytes or from the hepatobiliary route can be recovered back to the precursor (aglycone) through bacteria-mediated hydrolysis. As a result, the pharmacokinetics [e.g., plasma terminal half-life (T1/2)] of aglycone might be altered. Here, impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone is evaluated using physiologically based pharmacokinetic (PBPK) models with liver and/or intestine as eliminating organs. It is found that compared with its absence, the presence of intestinal glucuronide hydrolysis leads to increases in the oral systemic bioavailability (Fsys) of aglycone. The magnitude of fold increase is positively correlated with the level of metabolism, as metabolic clearance mainly contributes to recycled amount of glucuronide. Although Fsys is independent of the glucuronide efflux in a traditional model and a segregated-flow model of the intestine, dependence of Fsys on the glucuronide efflux can be observed in a segmental segregated-flow model of the intestine and whole-body PBPK models. Interestingly, when the ratio of apical versus basolateral efflux intrinsic clearances (of glucuronide) is fixed, their effects on the intestinal bioavailability and Fsys cease to exist. In addition, glucuronide hydrolysis can lead to a significantly delayed elimination of the aglycone as evidenced by a prolonged (e.g., a 2.1-fold increase) T1/2. Surprisingly, when a pharmacokinetic profile for aglycone is simulated with a flat terminal portion (a reflection of the experimental observations), changes in the aglycone bioavailabilities are limited (i.e., ≤1.3-fold). In conclusion, this study explores the possible role of intestinal glucuronide hydrolysis in the disposition of aglycone via simulations utilizing various PBPK models. The mechanistic observations should be helpful to better understand the complex glucuronidation in vivo. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association" @default.
• W2040341776 created "2016-06-24" @default.
• W2040341776 creator A5040226048 @default.
• W2040341776 date "2012-03-01" @default.
• W2040341776 modified "2023-09-25" @default.
• W2040341776 title "Use of Physiologically Based Pharmacokinetic Models to Evaluate the Impact of Intestinal Glucuronide Hydrolysis on the Pharmacokinetics of Aglycone" @default.
• W2040341776 cites W1982052181 @default.
• W2040341776 cites W1984538844 @default.
• W2040341776 cites W1991359947 @default.
• W2040341776 cites W1994627863 @default.
• W2040341776 cites W1995053750 @default.
• W2040341776 cites W1999972814 @default.
• W2040341776 cites W2029886788 @default.
• W2040341776 cites W2033768177 @default.
• W2040341776 cites W2042584507 @default.
• W2040341776 cites W2051732510 @default.
• W2040341776 cites W2061587734 @default.
• W2040341776 cites W2064931573 @default.
• W2040341776 cites W2066910350 @default.
• W2040341776 cites W2071480947 @default.
• W2040341776 cites W2075585148 @default.
• W2040341776 cites W2076052464 @default.
• W2040341776 cites W2096618362 @default.
• W2040341776 cites W2101393342 @default.
• W2040341776 cites W2101686121 @default.
• W2040341776 cites W2107262592 @default.
• W2040341776 cites W2107430154 @default.
• W2040341776 cites W2116774028 @default.
• W2040341776 cites W2140145798 @default.
• W2040341776 cites W2151349499 @default.
• W2040341776 cites W300443401 @default.
• W2040341776 doi "https://doi.org/10.1002/jps.22827" @default.
• W2040341776 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22109716" @default.
• W2040341776 hasPublicationYear "2012" @default.
• W2040341776 type Work @default.
• W2040341776 sameAs 2040341776 @default.
• W2040341776 citedByCount "20" @default.
• W2040341776 countsByYear W20403417762012 @default.
• W2040341776 countsByYear W20403417762013 @default.
• W2040341776 countsByYear W20403417762014 @default.
• W2040341776 countsByYear W20403417762015 @default.
• W2040341776 countsByYear W20403417762016 @default.
• W2040341776 countsByYear W20403417762017 @default.
• W2040341776 countsByYear W20403417762019 @default.
• W2040341776 countsByYear W20403417762020 @default.
• W2040341776 countsByYear W20403417762021 @default.
• W2040341776 countsByYear W20403417762023 @default.
• W2040341776 crossrefType "journal-article" @default.
• W2040341776 hasAuthorship W2040341776A5040226048 @default.
• W2040341776 hasConcept C112705442 @default.
• W2040341776 hasConcept C181199279 @default.
• W2040341776 hasConcept C181389837 @default.
• W2040341776 hasConcept C185592680 @default.
• W2040341776 hasConcept C185867374 @default.
• W2040341776 hasConcept C194671627 @default.
• W2040341776 hasConcept C200082930 @default.
• W2040341776 hasConcept C2777477808 @default.
• W2040341776 hasConcept C2779186261 @default.
• W2040341776 hasConcept C2779396346 @default.
• W2040341776 hasConcept C2779907587 @default.
• W2040341776 hasConcept C2781278898 @default.
• W2040341776 hasConcept C55493867 @default.
• W2040341776 hasConcept C71240020 @default.
• W2040341776 hasConcept C86803240 @default.
• W2040341776 hasConcept C87644729 @default.
• W2040341776 hasConcept C98274493 @default.
• W2040341776 hasConceptScore W2040341776C112705442 @default.
• W2040341776 hasConceptScore W2040341776C181199279 @default.
• W2040341776 hasConceptScore W2040341776C181389837 @default.
• W2040341776 hasConceptScore W2040341776C185592680 @default.
• W2040341776 hasConceptScore W2040341776C185867374 @default.
• W2040341776 hasConceptScore W2040341776C194671627 @default.
• W2040341776 hasConceptScore W2040341776C200082930 @default.
• W2040341776 hasConceptScore W2040341776C2777477808 @default.
• W2040341776 hasConceptScore W2040341776C2779186261 @default.
• W2040341776 hasConceptScore W2040341776C2779396346 @default.
• W2040341776 hasConceptScore W2040341776C2779907587 @default.
• W2040341776 hasConceptScore W2040341776C2781278898 @default.
• W2040341776 hasConceptScore W2040341776C55493867 @default.
• W2040341776 hasConceptScore W2040341776C71240020 @default.
• W2040341776 hasConceptScore W2040341776C86803240 @default.
• W2040341776 hasConceptScore W2040341776C87644729 @default.
• W2040341776 hasConceptScore W2040341776C98274493 @default.
• W2040341776 hasIssue "3" @default.
• W2040341776 hasLocation W20403417761 @default.
• W2040341776 hasLocation W20403417762 @default.
• W2040341776 hasOpenAccess W2040341776 @default.
• W2040341776 hasPrimaryLocation W20403417761 @default.
• W2040341776 hasRelatedWork W2014232034 @default.
• W2040341776 hasRelatedWork W2015484631 @default.
• W2040341776 hasRelatedWork W2040341776 @default.
• W2040341776 hasRelatedWork W2062880058 @default.
• W2040341776 hasRelatedWork W2076052464 @default.
• W2040341776 hasRelatedWork W2095943039 @default.
• W2040341776 hasRelatedWork W2110049826 @default.
• W2040341776 hasRelatedWork W2273335235 @default.
• W2040341776 hasRelatedWork W2587902810 @default.
• W2040341776 hasRelatedWork W3092223869 @default.

• next